ADMA Biologics (NASDAQ:ADMA) and Titan Pharmaceuticals (NASDAQ:TTNP) Financial Comparison

Titan Pharmaceuticals (NASDAQ:TTNP) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Titan Pharmaceuticals and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Titan Pharmaceuticals	N/A	-87.90%	-75.11%
ADMA Biologics	10.53%	38.79%	17.35%

Volatility and Risk

Titan Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Titan Pharmaceuticals and ADMA Biologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Pharmaceuticals	$180,000.00	26.31	-$5.57 million	N/A	N/A
ADMA Biologics	$330.24 million	13.88	-$28.24 million	($0.02)	-988.50

Titan Pharmaceuticals has higher earnings, but lower revenue than ADMA Biologics.

Institutional & Insider Ownership

31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 24.9% of Titan Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Titan Pharmaceuticals and ADMA Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Pharmaceuticals	0	0	0	0	N/A
ADMA Biologics	0	0	3	1	3.25

ADMA Biologics has a consensus target price of $15.50, indicating a potential downside of 21.60%. Given ADMA Biologics’ higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Titan Pharmaceuticals.

Summary

ADMA Biologics beats Titan Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.